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Abstract
Purpose
Systemic inflammation and coronary microvascular dysfunction (CMD) may be causal driv-
ers of heart failure with preserved ejection fraction (HFpEF). We tested the hypothesis that
subclinical inflammation is associated with non-endothelial dependent CMD and diastolic
dysfunction.
Methods
In a cross-sectional study of 336 women with angina but no flow limiting coronary artery ste-
nosis (180 with diabetes) and 95 asymptomatic controls, blood samples were analysed for
90 biomarkers of which 34 were part of inflammatory pathways. CMD was assessed as cor-
onary flow velocity reserve (CFVR) by transthoracic Doppler echocardiography and defined
as CFVR<2.5. We used E/e’ as an indicator of diastolic function in age-adjusted linear
regressions to assess correlations between biomarkers, CFVR and diastolic function.
Results
CMD was found in 59% of participants whereas only 4% fulfilled strict criteria for diastolic
dysfunction. Thirty-five biomarkers, 17 of them inflammatory, were negatively correlated
with CFVR and 25, 15 inflammatory, were positively correlated with E/e’. A total of 13 bio-
markers, 9 inflammatory, were associated with both CFVR and E/e’. CFVR and E/e’ were
only correlated in the subgroup of patients with CMD and signs of increased filling pressure
(E/e’>10) (p = 0.012).
Conclusion
This is the first study to link a large number of mainly inflammatory biomarkers to both CMD
and E/e’, thus confirming a role of inflammation in both conditions. However, despite a high
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prevalence of CMD, few patients had diastolic dysfunction and the data do not support a
major pathophysiologic role of non-endothelial dependent CMD in diastolic dysfunction.
1 Introduction
Coronary microvascular dysfunction (CMD) is associated with increased mortality, even in
the absence of macrovascular coronary artery disease (CAD) [1, 2]. Among patients with
heart failure with preserved ejection fraction (HFpEF) the prevalence of CMD was recently
found to be high [3] and it has been suggested that CMD plays a pathophysiological role in the
development [4]. Multiple comorbidities including diabetes, hypertension and dyslipidemia
contribute to a pro-inflammatory state that induces oxidative stress in the microvascular endo-
thelium, leading to both endothelial dependent or non-endothelial dependent CMD [4, 5].
Because of cross-talk between endothelial cells and cardiomyocytes, endothelial inflammation
may ultimately lead to myocardial functional alterations [6–8], contributing to adverse cardiac
prognosis [9, 10]. The same comorbidities mentioned above that have been associated with
microvascular dysfunction have been associated with cardiac diastolic dysfunction [11, 12].
Further, it has been suggested that angina with no obstructive CAD is pathophysiologically
linked to HFpEF [13], but evidence supporting a direct pathophysiological link between CMD
and cardiac diastolic dysfunction remains limited [14].
In smaller studies we have previously found several biomarkers of inflammation and vascu-
lar dysfunction to be associated with non-endothelial dependent CMD in women with angina
symptoms but no flow limiting CAD [15, 16]. Here we explore the hypothesis that subclinical
inflammation is linked to coronary microvascular function and cardiac diastolic function, and
that the effect of inflammation on diastolic function is partly mediated by non-endothelial
dependent CMD (Fig 1).
2 Methods
2.1 Population
We explored this hypothesis in a population of diabetic (Group A) and non-diabetic (Group
B) women with angina and no flow limiting CAD from the iPOWER (ImProve diagnOsis and
treatment of Women with angina pEctoris and micRovessel disease) study as well as in con-
trols (Group C). The iPOWER study has been described in detail previously [17, 18] and com-
prises 1830 women with angina symptoms and no obstructive CAD defined as <50%
coronary artery stenosis assessed by clinically indicated invasive coronary angiogram in east-
ern Denmark between March 2012 and December 2017. The control group consisted of
asymptomatic women without diabetes or previous cardiovascular disease (Group C)
recruited from the Copenhagen City Heart Study, a population based prospective study [19].
Patients with diabetes and asymptomatic controls were chosen to achieve a broad spectre of
microvascular and diastolic function. Therefore, samples were not matched on baseline
characteristics.
The iPOWER study was performed in accordance with the Helsinki Declaration and was
approved by the Danish Regional Committee on Biomedical Research Ethics (H-3-2012-005).
All participants gave written informed consent on oral and written information.
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2.2 Examinations
Assessments included demographics, risk factors, clinical data (age, body mass index (BMI),
hypertension, hypercholesterolemia, smoking, and medication) and a fasting blood sample
analysis.
Participants underwent a standard resting transthoracic echocardiography with measure-
ments of systolic and diastolic function using GE Healthcare Vivid E9 cardiovascular ultra-
sound system (GE Healthcare, Horten, Norway) with a 1.3–4.0 MHz transducer (GE Vivid 5S
probe). Images were stored for off-line analysis (GE EchoPAC v.112, Norway). Please see S1
Data in S1 File: Echocardiographic examination, for a description of the evaluation of diastolic
function. We used E/e’ as an indicator of diastolic function in linear regression analyses as has
been done in other studies [20, 21].
Microvascular function was assessed by transthoracic Doppler echocardiography (TTDE)
measuring coronary flow velocity (CFV) of the left anterior descending artery (LAD) during
rest and dipyridamole infusion (0.84 mg/kg) over 6 minutes using a 2.7–8 MHz transducer
(GE Vivid 6S probe) as previously described [18, 22]. Coronary flow velocity reserve (CFVR),
was calculated as the ratio of peak diastolic CFV during dipyridamole induced hyperemia and
rest. Please see S1 Data in S1 File: Echocardiographic examination, for a thorough description
of the echocardiographic examinations.
2.3 Protein biomarkers
Blood samples were analyzed by Olink Proteomics, Uppsala, Sweden using the predefined car-
diovascular disease panel III, measuring 90 protein biomarkers related to the cardiovascular
system by real-time polymerase chain reaction. For further description of the method please
see S2 Data in S1 File: Biomarker analysis and intensity normalization. It is a well-designed
Fig 1. Hypothetical pathway from inflammation to diastolic dysfunction. The underlying hypothesis linking inflammation, coronary microvascular
function and diastolic dysfunction through causal pathways. The pathways explored in the current paper are depicted with red arrows.
https://doi.org/10.1371/journal.pone.0236035.g001
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panel of which 34 of 90 biomarkers are classified by the provider as inflammatory, but of the
remaining, many are poorly characterized and may also be involved in inflammatory pro-
cesses. The panel has been used by other investigators, including HFpEF studies [20] and is
therefore interesting to explore further.
2.4 Statistical analysis
Differences in baseline patient characteristics across groups were analyzed for linear trends by
linear regression for continuous outcome variables. Variables with non-Gaussian distribution
were naturally log transformed before the analysis which resulted in an approximated Gauss-
ian distribution. Logistic regression analysis was used for categorical outcome variables. Level
of biomarker, E/e’ (as an indicator of diastolic function) and CFVR were compared across
groups by trend test in age adjusted linear regression.
Since a previous study found association between CMD and E/e’ only in a subgroup with
impaired CFVR and E/e’ [23] separate additional regression analyses were performed in a sub-
population with CMD defined as CFVR<2.5 and signs of diastolic impairment defined as
E/e’>10. Cut-offs were chosen to include subjects with poor microvascular function and signs
of diastolic impairment while keeping the population size sufficiently large for further analyses.
In this sub-analysis, three outliers were found to be influential. After values were checked for
correctness we found they could not be removed from the dataset, and we examined the data
with a robust regression analysis including information on leverage and residual of the
observations.
Initial exploratory analyses were performed investigating the relation between each of the
90 biomarkers and CFVR and E/e’, respectively, in regression models as explained above,
adjusted for age. To ease comparison across biomarkers, values were transformed to z-scores.
We did not perform Bonferroni correction, since we considered the analysis exploratory and
our aim was not to identify a single or a few explanatory biomarkers, but to explore possible
associations suggestive of an effect of inflammation.
We used a principal component analysis (PCA) to examine biomarker interrelations in
the 34 biomarkers defined by the provider as mainly linked to inflammation. Our intention
with the PCA was not to reduce data to fewer explanatory components, but to explore the
communality within the biomarkers. All 34 inflammatory biomarkers were highly corre-
lated, and all loaded principally and equally on the first component in the PCA. Therefore,
we defined a common inflammation index as the mean level of the 34 inflammatory bio-
markers. To explore whether CFVR may mediate a causal effect between inflammation and
diastolic dysfunction, we performed a mediation analysis using this inflammation index in
predicting E/e’ through CFVR in the subgroup defined above (CFVR<2.5 and E/e’>10)
(Fig 1). The mediation analysis can formally assess if any association between inflammation
and E/e’ is created (ie. mediated) by an effect of inflammation on CFVR, which then in
turn affects E/e’. A detailed description of mediation analysis and the mathematical back-
ground can be found in Lange et al [24] and is implemented using the R package medflex
[25, 26].
Continuous variables with a Gaussian distribution are expressed as mean ± standard devia-
tion (SD) or mean-max values, and continuous variables with a non-Gaussian distribution as
appropriate. A two-sided p-value below 0.05 was considered significant. All analyses were per-
formed using STATA/IC 13.1 (StataCorp LP, College Station, Texas, USA), except for the
mediation analysis which was performed using the R package medflex.
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3 Results
After excluding participants without CFVR examination (n = 18) or poor quality CFVR mea-
surement (n = 20) we included 180 women with a diagnosis of diabetes and 156 women with-
out diabetes from the iPOWER cohort [17]. From the Copenhagen City Heart Study cohort,
we included a control sample of 95 women [19]. Baseline characteristics are presented in
Table 1.
Women with diabetes were older and, as expected, had a higher burden of risk factors com-
pared with non-diabetic patients with and without angina symptoms. Furthermore, they were
more likely to have diffuse atheromatosis than non-diabetic angina patients. There was a clear
trend of more medical treatment in patients with angina which was also reflected in biochemi-
cal measurements of cholesterol levels. Patients with diabetes had well-regulated blood sugar
with median (IQR) Hba1c of 50 (45, 61) mmol/l.
Table 1. Population characteristics across the three groups.
Women with angina and no obstructive CAD Controls
Group A Group B Group C
Diabetes (n = 180) No diabetes (n = 156) Control (n = 95) p†
Clinical data (mean(SD) / median(IQR) / n (%))
Age, years 64 (36,80) 62 (32,80) 61 (32,81)� 0.003
BMI 30.7 (15.2, 45.5) 26.1 (18.6,40.0)� 24.7 (18.6,38.4)� <0.001
BP, mmHg 135 (23) 129 (19)� 116 (17)� <0.001
HR at rest, beats/min 73 (12) 66 (19)� 68 (13)� <0.001
Hypertension 133 (75) 85 (55)� 15 (18)� <0.001
Ever-smoker 78 (44) 99 (64)� 50 (58)� 0.007
Hypercholesterolemia 145 (82) 98 (63)� 15 (18)� <0.001
Atheromatosis (on CAG) 83 (49) 54 (35)� 0.244
Postmenopausal 151 (84) 129 (83) 74 (78)
Medication (n (%))
ASA 105 (59) 67 (43)� 3 (3)� <0.001
BB 60 (34) 48 (31) 3 (3)� <0.001
ACE-I 45 (26) 24 (16)� 4 (4)� <0.001
ANGII-blocker 62 (35) 24 (16)� 6 (6)� <0.001
Statin 135 (76) 73 (47)� 6 (6)� <0.001
Biochemical measures (median (IQR))
HbA1c, mmol/mol 50 (45, 61) 37 (34, 39)� 35 (34, 38)� <0.001
Total cholesterol, mmol/L 4.2 (3.7, 4.8) 5.0 (4.3, 5.7)� 5.3 (4.9, 5.8)� <0.001
HDL-cholesterol, mmol/L 1.4 (1.1, 1.7) 1.7 (1.4, 2)� 1.8 (1.6, 2.2)� <0.001
LDL-cholesterol, mmol/L 2 (1.5, 2.6) 2.7 (2, 3.7)� 2.9 (2.5, 3.5)� <0.001
Triglyceride, mmol/L 1.4 (1, 2) 1.0 (0.8, 1.4)� 0.9 (0.7, 1.1)� <0.001
Creatinine, μmol/L 62 (55, 71) 65 (58, 74) 67 (61, 74)� 0.030
U-albumin/creatinin ratio 1.3 (0.7, 3.2) 1.0 (0.8, 1.4)� 0.5 (0.3, 1.2)� <0.001
† Unadjusted trend test from linear or logistic regression.
�p<0.05 compared with group A.
CAG coronary angionagram, CAD coronary artery disease, CVD cardiovascular disease, BMI body mass index, BP blood pressure, HR heart rate, ASA acetyl salicylate,
BB beta blocker, ACE-I angiotensin converting enzyme inhibitor, ANGII angiotensin II receptor.
https://doi.org/10.1371/journal.pone.0236035.t001
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3.1 CFVR
Median CFVR (IQR) ranged from 2.22 (1.90, 2.56) in the diabetes group to 2.35 (1.96, 2.74) in
the symptomatic non-diabetes group and 2.63 (2.22, 3.08) in controls (p for trend<0.001)
(Table 2).
Results did not change after adjusting for age and heart rate at rest. CFV at hyperemia was
similar between groups and the lower CFVR was mainly due to higher baseline CFV in the
angina patients. The proportion with CMD defined as CFVR<2.5 was 69% in group A, 58% in
group B and 38% in group C (p<0.001). The proportion of participants with severe CMD
(CFVR<2) was 34% in group A, 27% in group B and 14% in group C.
3.2 Systolic and diastolic cardiac function
Several indices of systolic and diastolic function showed a significant trend of poorer function
in patients with diabetes compared with nondiabetic women with and without angina symp-
toms. However, only 4% fulfilled strict criteria for diastolic dysfunction (Please see S1 Data in
S1 File: Echocardiographic examination, for the definition). GLS was significantly lower
among patients with diabetes whereas E/A ratio, e’, E/e’ and LAI all pointed towards more
impairment of diastolic function across groups (p all<0.001). No trend was seen for decelera-
tion time (DECT) and LVMI showed a weak inverse trend (p = 0.02). However, the absolute
LV mass did not differ significantly between groups.
3.3 Biomarkers
Biomarkers were available in 395 study participants. All 90 biomarkers passed quality control
criteria and>95% of the measured proteins were detected in all samples. After age adjustment,
34 biomarkers were significantly associated with CFVR, and all had a negative association, i.e.
a higher CFVR was associated with a lower level of biomarkers. Of those, 17 were part of the
34 biomarkers in the inflammatory panel (referring to the pathway from inflammation
Table 2. Echocardiographic measures compared across the three groups.
Women with angina and no obstructive CAD Controls
Measure,
Mean (SD) / median (IQR)
Group A Group B Group C
Diabetes (n = 180) No diabetes (n = 156) Control (n = 95) p for trend
CFVR 2.22 (1.90, 2.56) 2.35 (1.96, 2.74) 2.63 (2.22, 3.08)� <0.001
CFV at rest, m/s 0.24 (0.20, 0.31) 0.23 (0.19, 0.29) 0.21 (0.19, 0.25)� 0.002
CFV at hyperemia, m/s 0.55 (0.45, 0.63) 0.56 (0.47, 0.68) 0.57 (0.49, 0.66) 0.290
GLS at rest, % 20.32 (2.73) 21.28 (3.24)� 21.09 (2.75) 0.018
E/A ratio 0.91 (0.78, 1.05) 0.98 (0.83, 1.13) 1.11 (0.94, 1.33)� <0.001
e’ (lateral and septal), cm/s 7.89 (2.16) 9.05 (2.28)� 9.49 (2.32)� <0.001
E/e’ ratio 9.79 (8.14, 12.21) 8.07 (6.85, 9.95)� 7.86 (6.89, 9.58)� <0.001
LAI, mL/m2 26.91 (21.36, 32.36) 26.44 (22.20, 34.15) 22.08 (19.30, 28.06)� <0.001
LVMI, g/m2 71.28 (61.70, 80.70) 73.01 (62.29, 81.46) 75.53 (65.09, 84.55) 0.023
LV mass, g 132.79 (116.07, 155.43) 129.38 (110.02, 150.57) 139.55 (114.68, 158.30) 0.811
DECT, ms 192 (165, 225) 179 (156, 210) 193 (179, 213) 0.522
† Unadjusted trend test from linear or logistic regression.
�p<0.05 compared with group A.
CFVR coronary flow velocity reserve, CFV coronary flow velocity, GLS global longitudinal strain measured as peak systolic strain, LAI left atrial volume indexed by
body surface area, LVMI left ventricular myocardial index, DECT deceleration time.
https://doi.org/10.1371/journal.pone.0236035.t002
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through non-endothelial dependent coronary microvascular dysfunction to diastolic dysfunc-
tion in Fig 1). 26 biomarkers were significantly associated with E/e’, 25 with a positive associa-
tion, and 15 were in the inflammatory panel (referring to the pathway from inflammation to
cardiac diastolic dysfunction depicted in Fig 1). There was an overlap of thirteen biomarkers,
significantly associated with both CFVR and E/e’ with 9 being part of the inflammatory panel
(please see Fig 2 and S3A Table in S1 File: Biomarker correlations with CFVR and E/e’ after
age-adjustment).
The PCA indicated high communality between the inflammatory biomarkers. The com-
bined inflammation score showed significant correlation with both CFVR and E/e’ after age
adjustment (p = 0.013 and 0.019, respectively).
Levels of biomarkers across groups A, B and C are shown in S4A Table in S1 File: Level of
biomarker across study groups. Of the 47 biomarkers associated with CFVR and/or E/e’, 41
showed a significant negative trend across the groups and no significant trend was found in
the remaining 6 of these biomarkers.
CMD and diastolic function. We did not find an association between diastolic function
measured as E/e’ and CFVR in the overall study population (Fig 3) (referring to the pathway
from inflammation through non-endothelial dependent coronary microvascular dysfunction
to diastolic dysfunction depicted in Fig 1).
When we restricted the analysis to patients with CFVR<2.5 and E/e’>10 (n = 79) there was
a significant association (p = 0.012). Three outliers were found to be influential but they could
not be removed after being checked for correctness. However, the association did not reach
significance when the outliers were excluded from the regression analysis (p = 0.066). Since
Fig 2. Overview of biomarkers associated with CFVR and E/e’ by level of significance. The red line dividing the
graph in four squares marks a significance level of 0.05 on both axes. Lower left quadrant shows the 13 biomarkers
significantly associated with both CFVR and E/e’ with inflammatory biomarkers marked with open circles. Biomarkers
significantly associated with CFVR in the upper left corner (green dots) and biomarkers significantly associated with
E/e’ in the lower right corner (blue dots).
https://doi.org/10.1371/journal.pone.0236035.g002
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the outliers could not be removed and the association therefore reached significance, we pro-
ceeded with a mediation analysis. It did not support that the effect of inflammation on diastolic
function was mediated by impaired microvascular function in this subpopulation (indirect
effect 0.005 (CI -0.011–0.021)), perhaps because of lack of statistical power (only participants
with biomarker measurements were included in this analysis (n = 73)). CFVR was associated
with other measures of diastolic impairment: E/A (p = 0.013), and LAI (p = 0.039) but not
with the combined lateral and medial e’ (p = 0.073) or DECT (p = 0.818).
4 Discussion
This is the first study linking data on multiple biomarkers to non-endothelial dependent coro-
nary microvascular function and diastolic function in a large, well-characterized study popula-
tion. The main finding was that non-endothelial dependent CMD and E/e’ were significantly
associated with more than half of the biomarkers studied. Of the 13 biomarkers significantly
associated with both CFVR and E/e’, 9 were part of inflammatory pathways, thus providing
empirical support to the hypothesis linking inflammation to CMD and diastolic function in
patients suspected of microvascular angina as depicted in Fig 1. However, despite a high preva-
lence of non-endothelial dependent CMD, diastolic dysfunction was not prevalent in the pop-
ulation which questions a direct causal role of non-endothelial dependent CMD in the
pathogenesis of diastolic dysfunction and HFpEF.
4.1 Non-endothelial CMD and diastolic dysfunction
An underlying hypothesis of the study was that CMD is associated with diastolic dysfunction.
The prevalence of CMD was high in the present study, 59% of the patients had CMD defined
as CFVR<2.5 and 27% had CFVR<2.0. However, although in particular patients with diabetes
Fig 3. Association between E/e’ and CFVR in the total population. The graph illustrates the effect of E/e’ on CFVR
in the total population. Linear regression is performed with both variables naturally log transformed.
https://doi.org/10.1371/journal.pone.0236035.g003
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had signs of poorer diastolic function, measures were still within a normal range and very few
individuals reached the cut-off value indicating diastolic dysfunction (4% among diabetics and
none in the other groups). Overall, there was no correlation between CFVR and E/e’, yet we
did see an association between CFVR and E/e’ in a subgroup with CMD and E/e’>10. The
association, however, was dependent on three influential outliers thus these results should be
interpreted with caution and can only be regarded as hypothesis-generating. The data did not
directly support a mediating role of non-endothelial CMD in the pathway from inflammation
to diastolic function in this subgroup but statistical power was limited and furthermore, it is
possible that our study population was too healthy. Importantly, in a prospective study linking
non-endothelial dependent coronary microvascular function to development of HFpEF, CFR
and E/e’ were inversely correlated only in patients with CFR<2 [23]. In this study of 201
patients without obstructive CAD, E/e’ values were considerably higher than in the present
study indicating more advanced stages of disease. In another recent multicenter study of 202
patients diagnosed with HFpEF, the prevalence of CMD was also high [3]. Thus, our results
are not contradictory to previous studies but complement them by including also patients with
CMD with normal or near-normal diastolic function. Taken together these cross-sectional
studies cannot determine whether CMD is a cause or a consequence of diastolic dysfunction
but the low prevalence of diastolic dysfunction among patients with impaired microvascular
function indicate that non-endothelial dependent CMD is not a strong risk factor for HFpEF.
However, our study consisted of a selected population of women in which ethnic origin was
not addressed, thus, we cannot rule out that gender differences or race differences may exist,
and our results cannot be extrapolated to other patient populations. It is possible that endothe-
lial dependent CMD, which we did not evaluate, is associated with development of diastolic
dysfunction. A systemic pro-inflammatory state reduces endothelial nitric oxide synthase
activity in coronary endothelial cells, limiting bioavailability for cardiomyocytes. In a preclini-
cal model Schiattarella et al. recently presented evidence that metabolic inflammation and NO
synthase are critical in the pathophysiology of HFpEF [27]. MicroRNAs have emerged as
another promising tool to identify HFpEF. MicroRNA panels combined with N-terminal pro-
B-type natriuretic peptide (NT-proBNP) have shown improved specificity and accuracy in
identifying HFpEF in a study of 1710 patients with and without heart failure [28]. Further-
more, microRNAs have shown aetiology-specific transcoronary concentration gradients in
heart failure suggesting that microRNAs may be useful biomarkers to distinguish heart failure
of different a etiologies [29]. Additionally, preclinical studies have suggested that microRNAs
may be released upon ischemia and modulate endothelial function and vascular remodeling
on remote vascular beds [30]. Therefore, it may also be a tool to identify early changes in vas-
cular function which awaits further clarification in future clinical studies. In the present study,
however, NT-proBNP was not associated with neither CFVR nor E/e’, which is in accordance
with previous results suggesting that NT-proBNP level is a better marker in HFrEF [31].
4.2 Inflammation
Chronic, subclinical inflammation and its association with cardiovascular disease has been
studied extensively in the past years. Previous studies have found increased levels of a number
of inflammatory biomarkers in asymptomatic left ventricular systolic- and diastolic dysfunc-
tion [32, 33], and inflammatory markers have been associated with increased risk of develop-
ing heart failure [34, 35]. Inflammation has also been associated with CMD in several studies
[15, 36–40], however, studies were small, study populations selected, and most studies
included only a few biomarkers. In this exploratory analysis, out of 90 biomarkers 34 had a sig-
nificant negative correlation with CFVR, 25 had a significant positive correlation with E/e’, i.e.
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far more associations than can be explained by chance. Further, the inflammation index was
significantly associated with both CFVR and E/e’. These results confirm a link between inflam-
mation and CMD and diastolic dysfunction, respectively, as found in previous studies, and
extend them to include a large number of biomarkers that may increase understanding of the
pathophysiology behind the conditions.
In line with our findings, several of the biomarkers we found to be associated with both
CFVR and E/e’ were also significantly correlated with E/e’ in a prognostic study of 86 patients
with HFpEF by Hage et al.: Growth differentiation factor 15 (GDF-15), Tumor necrosis factor
receptor 1 (TNFR1), Chitinase-3-like protein 1 (CHI3L1), Fatty acid-binding protein 4
(FABP4) and Soluble urokinase-type plasminogen activator receptor (sUPAR) [20]. In another
study TNFR2 levels were significantly associated with increasing E/e’ ratio and grade of dia-
stolic dysfunction in 100 patients with HFpEF, while both TNFR1 and TNFR2 levels were sig-
nificantly associated with impaired NYHA functional status [21]. In the present study we have
found several biomarkers that reflect complex interactions in the cardiovascular system, and
the interplay and consequences are not fully understood. In line with this, a recent study found
that a combination of biomarker correlations was associated with HFpEF in 431 patients, and
that the majority of the biomarkers were related to inflammation [41]. The broad range of bio-
markers with involvement in different biological processes may reflect the heterogeneity of
both coronary microvascular function and cardiac diastolic function, and it complicates char-
acterization of these entities to a great extent.
4.3 Strengths and limitations
To our knowledge this is the largest study exploring an association between a wide range of
biomarkers, non-endothelial dependent CMD and cardiac diastolic function. Strengths of
the study include the prospective design and that patients were included consecutively
among patients undergoing angiography and are therefore less subject to selection bias.
However, our study must be considered exploratory due to the large number of examined
biomarkers in relation to our population size. The serial analyses performed in this study nat-
urally introduces risk of type I error and the findings should be reproduced in other studies
of CMD and as touched upon above, our attempt to achieve extremes of CMD and diastolic
function by including patients with diabetes was somewhat undermined by the fact that dia-
stolic dysfunction was less prevalent than expected. We induced hyperemia by dipyridamole
infusion which evaluates primarily non-endothelium dependent vasodilatation. Results are
not applicable to endothelial dependent coronary vascular function assessed by e.g. acetyl-
choline provocation.
4.4 Conclusions
In this hitherto largest study of cardiovascular biomarkers, coronary microvascular function
and cardiac diastolic function we have provided evidence of an association between inflamma-
tion and CMD and diastolic function respectively, in a population of women with and without
diabetes and with and without angina symptoms. The results suggest that inflammation plays
a role in both non-endothelial dependent CMD and diastolic dysfunction, but our data did not
support a common pathogenetic pathway between these conditions. This study was performed
in a selected patient population and the results cannot be extrapolated to other patient groups.
Associations found in this study may be explained by common risk factors and causality must
be determined in future studies. Thus, well designed prospective studies are needed to clarify
the causality pathway.
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